Drugs / VNP20009
last change Jan 2008 re-read 2 minutes ago

VNP20009

Other / unclassified

Developed for
cancer of unknown primary site · cancer · metastatic neoplasm
Investigated by
Vion Pharmaceuticals · National Cancer Institute (NCI)

Trials 3 · a red edge is where a trial was stopped

19992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT00006254 May 2000 → Jan 2008 cancer of unknown primary site Vion Pharmaceuticals Completed No outcome recorded
Phase 1 NCT00004988 Mar 2000 → Oct 2002 cancer, metastatic neoplasm National Cancer Institute (NCI) Completed No outcome recorded
Phase 1 NCT00004216 Aug 1999 → Jan 2008 cancer of unknown primary site Vion Pharmaceuticals Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as VNP20009 ClinicalTrials.gov intervention name — accepted as the source's own label NCT00006254
2

NCT00004216

NCT00004988

Modality Other / unclassified “live, genetically modified Salmonella typhimurium (VNP20009)” NCT00004216
Route Other “intratumorally injected live, genetically modified Salmonella typhimurium (VNP20009)” NCT00004216